Nintedanib ophthalmic nanosuspension (Allgenesis Biotherapeutics)

尼达尼布眼用纳米混悬剂 (Allgenesis Biotherapeutics)

Report date: 2025/03/12 15:19:38

First In Class

Base Information

Drug NameNintedanib ophthalmic nanosuspension (Allgenesis Biotherapeutics)

Drug Alias Name尼达尼布AG-86893

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[10]

TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[10]

Therapy Area/IndicationsPterygium

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAllgenesis Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAllgenesis Biotherapeutics Inc

Active IndicationsN/A

Inactive IndicationsPterygium

Other Information

ATC CodeN/A